



Complicated Cataract Cases (02/12/22 @ 8 a.m. ET)

Saturday, February 12, 2022

Online

Program Chair(s):

Robert Lehman, MD

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

At the conclusion of the course, participants should be able to:

- 1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eye diseases.
- 2 Identify basic and clinical vision research that can be transformed into improved clinical care.
- 3 Assess the role of new technologies in the evaluation and treatment of eye diseases.
- 4 Describe factors that impact the effective delivery of the highest quality eye care for the public.
- 5 Identify clinical, scientific, and ethical issues confronting the profession.
- 6 Obtain information and tools through multiple facets to help ophthalmologists deliver high and efficient quality of care.

Accreditation Statement:

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Wills Eye Hospital designates this live educational activity for a maximum of 4.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Robert Lehman, MD	Course Director, Faculty	Nothing to disclose - 02/11/2022
Robert S Bailey, MD	Faculty	Nothing to disclose - 02/05/2022
Mark Blecher, MD	Faculty	Consulting Fee-Johnson & Johnson - 02/09/2022
John Epstein, MD	Faculty	Nothing to disclose - 02/09/2022
Brad H Feldman, MD	Faculty	Nothing to disclose - 04/27/2021
Omesh P. Gupta, MD, MBA	Faculty	Nothing to disclose - 03/21/2021
Sadeer B. Hannush, MD	Faculty	Nothing to disclose - 10/06/2021
Alessandra Intili, MD	Faculty	Nothing to disclose - 04/27/2021
Marlene R. Moster, MD	Faculty	Nothing to disclose - 04/03/2021
Sagun Pendse, MD	Faculty	Nothing to disclose - 06/24/2021
Mark F Pyfer, MD	Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Aerie Pharmaceuticals (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-EyePoint Pharmaceuticals (Relationship has ended) Speakers Bureau-EyeVance Pharmaceuticals (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Johnson & Johnson (Relationship has ended) Paid consultant-Johnson & Johnson Speakers Bureau-Omeros (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Omeros (Relationship has ended) Independent Contractor (included contracted research)-Sight Sciences Speakers Bureau-Sight Sciences Speakers Bureau-Rayner Surgical - 02/09/2022
S. Gregory Smith, MD	Faculty	Consulting Fee-PRN - 02/10/2022
Richard Tipperman, MD	Faculty	Advisor / Board Member-Alcon - 04/22/2021
Brett Weinstock, MD	Faculty	Nothing to disclose - 04/27/2021
Ralph C. Eagle Jr., MD	Other Planning Committee Member	Stocks or stock options, excluding diversified mutual funds-Merck - 01/15/2022

